Annegé Vledder

Annegé Vledder

Auto-generated profile, based on publicly available information

Annegé Vledder

University Medical Center Groningen 1 Department of Obstetrics and Gynaecology Groningen, the Netherlands

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
AEAnneke L. Eerkens
Anneke L. Eerkens
MEMartha D. Esajas
Martha D. Esajas
KBKoen Brummel
Koen Brummel
AVAnnegé Vledder
Annegé Vledder
NRNienke van Rooij
Nienke van Rooij
RYRefika Yigit
Refika Yigit
Purpose: Human papillomavirus (HPV) infection is the major cause of (pre)malignant cervical lesions. We previously demonstrated that Vvax001, a replication-incompetent Semliki Forest virus vaccine encoding HPV type 16 (HPV16) E6 and E7, induced potent anti-E6 and -E7 cytotoxic T-cell responses. In this study, we investigated the clinical efficacy of Vvax001 in patients with HPV16-positive cervical intraepithelial neoplasia (CIN) grade 3 (CIN3). Patients and Methods: Patients with newly diagnosed HPV16-positive CIN3 were eligible for participation. Patients received three immunizations of Vvax001 (5 × 107 infectious particles) at a 3-week interval. Up to 19 weeks after the last immunization, patients were monitored for regression of CIN3 by colposcopy. A colposcopy-guided biopsy was taken at the last visit, and a standard-of-care loop excision was performed only in case of remaining CIN grade 2/CIN3. Histopathologic response rates, HPV16 clearance, treatment-related adverse events, and vaccine-induced immune responses were assessed. Results: A total of 18 patients were enrolled and fully immunized. Colposcopic examination revealed a reduction in CIN3 lesion sizes in 17/18 (94%) patients already evident from 3 weeks onward after the last immunization. A histopathologic complete response (regression to CIN grade 1 or no dysplasia) was observed in 9/18 patients (50%) and HPV16 clearance in 10/16 patients (63%). Vvax001 did not induce clearance of other HPV types. To date, no recurrences have been observed, with a median and longest disease-free survival of 20 and 30 months, respectively. No serious adverse events were observed. Conclusions: Treatment with Vvax001 is safe and feasible and shows preliminary clinical effectiveness in patients with HPV16-associated CIN3 lesions.

22 August 2024 in International Journal of Cancer
Verified
Journal Article
Open access
AVAnnegé Vledder
Annegé Vledder
SPSterre T. Paijens
Sterre T. Paijens
DLDominik Loiero
Dominik Loiero
AMAlexis Maagdenberg
Alexis Maagdenberg
EDEvelien W. Duiker
Evelien W. Duiker
HNHans W. Nijman
Hans W. Nijman
Recent work has shown evidence for the prognostic significance of tumor infiltrating B cells (B‐TIL) in high grade serous ovarian carcinoma (HGSOC), the predominant histological subtype of ovarian cancer. However, it remains unknown how the favorable prognosis associated with B‐TIL relates to the current standard treatments of primary debulking surgery (PDS) followed by chemotherapy or (neo‐)adjuvant chemotherapy (NACT) combined with interval debulking surgery. To address this, we analyzed the prognostic impact of B‐TIL in relationship to primary treatment and tumor infiltrating T cell status in a highly homogenous cohort of HGSOC patients. This analysis involved a combined approach utilizing histological data and high‐dimensional flow cytometry analysis. Our findings indicate that while HGSOC tumors pre‐treated with NACT are infiltrated with tumor‐reactive CD8 + and CD4 + TIL subsets, only B‐TIL and IgA plasma blasts confer prognostic benefit in terms of overall survival. Importantly, the prognostic value of B‐TIL and IgA plasma blasts was not restricted to patients treated with NACT, but was also evident in patients treated with PDS. Together, our data point to a critical prognostic role for B‐TIL in HGSOC patients independent of T cell status, suggesting that alternative treatment approaches focused on the activation of B cells should be explored for HGSOC.

17 March 2025
Verified
Other
Open access
AEAnneke L. Eerkens
Anneke L. Eerkens
MEMartha D. Esajas
Martha D. Esajas
KBKoen Brummel
Koen Brummel
AVAnnegé Vledder
Annegé Vledder
NRNienke van Rooij
Nienke van Rooij
RYRefika Yigit
Refika Yigit
Purpose:Human papillomavirus (HPV) infection is the major cause of (pre)malignant cervical lesions. We previously demonstrated that Vvax001, a replication-incompetent Semliki Forest virus vaccine encoding HPV type 16 (HPV16) E6 and E7, induced potent anti-E6 and -E7 cytotoxic T-cell responses. In this study, we investigated the clinical efficacy of Vvax001 in patients with HPV16-positive cervical intraepithelial neoplasia (CIN) grade 3 (CIN3).Patients and Methods:Patients with newly diagnosed HPV16-positive CIN3 were eligible for participation. Patients received three immunizations of Vvax001 (5 × 107 infectious particles) at a 3-week interval. Up to 19 weeks after the last immunization, patients were monitored for regression of CIN3 by colposcopy. A colposcopy-guided biopsy was taken at the last visit, and a standard-of-care loop excision was performed only in case of remaining CIN grade 2/CIN3. Histopathologic response rates, HPV16 clearance, treatment-related adverse events, and vaccine-induced immune responses were assessed.Results:A total of 18 patients were enrolled and fully immunized. Colposcopic examination revealed a reduction in CIN3 lesion sizes in 17/18 (94%) patients already evident from 3 weeks onward after the last immunization. A histopathologic complete response (regression to CIN grade 1 or no dysplasia) was observed in 9/18 patients (50%) and HPV16 clearance in 10/16 patients (63%). Vvax001 did not induce clearance of other HPV types. To date, no recurrences have been observed, with a median and longest disease-free survival of 20 and 30 months, respectively. No serious adverse events were observed.Conclusions:Treatment with Vvax001 is safe and feasible and shows preliminary clinical effectiveness in patients with HPV16-associated CIN3 lesions.

17 March 2025
Verified
Other
Open access
PDF file
AEAnneke L. Eerkens
Anneke L. Eerkens
MEMartha D. Esajas
Martha D. Esajas
KBKoen Brummel
Koen Brummel
AVAnnegé Vledder
Annegé Vledder
NRNienke van Rooij
Nienke van Rooij
RYRefika Yigit
Refika Yigit
Supplementary Table S6. CD3+ immune infiltration.

17 March 2025
Verified
Other
Open access
PDF file
AEAnneke L. Eerkens
Anneke L. Eerkens
MEMartha D. Esajas
Martha D. Esajas
KBKoen Brummel
Koen Brummel
AVAnnegé Vledder
Annegé Vledder
NRNienke van Rooij
Nienke van Rooij
RYRefika Yigit
Refika Yigit
Supplementary Table S2. Univariate Cox regression for histopathologic regression following Vvax001 immunizations.

17 March 2025
Verified
Other
Open access
PDF file
AEAnneke L. Eerkens
Anneke L. Eerkens
MEMartha D. Esajas
Martha D. Esajas
KBKoen Brummel
Koen Brummel
AVAnnegé Vledder
Annegé Vledder
NRNienke van Rooij
Nienke van Rooij
RYRefika Yigit
Refika Yigit
Supplementary Table S7. CD8+ immune infiltration.